ADJUBIL: Phase II Study of Adjuvant Immunotherapy with STRIDE Regimen With/Without Capecitabine in Biliary Tract Cancers

References

• Jiang Y , JiangL, LiFet al. The epidemiological trends of biliary tract cancers in the United States of America. BMC Gastroenterol.22(1), 546 (2022).
   PubMed Web of Science ®Google Scholar
• Kish M , ChanK, PerryK, KoYJ. A systematic review and network meta-analysis of adjuvant therapy for curatively resected biliary tract cancers. Curr. Oncol.27(1), e20–e26 (2020).
   PubMed Web of Science ®Google Scholar
• Zhu GQ , ShiKQ, YouJet al. Systematic review with network meta-analysis: adjuvant therapy for resected biliary tract cancer. Aliment. Pharmacol. Ther.40(7), 759–770 (2014).
   PubMed Web of Science ®Google Scholar
• Edeline J , BenabdelghaniM, BertautAet al. Gemcitabine and Oxaliplatin Chemotherapy or Surveillance in Resected Biliary Tract Cancer (PRODIGE 12-ACCORD 18-UNICANCER GI): a randomized phase III study. J. Clin. Oncol.37(8), 658–667 (2019).
   PubMed Web of Science ®Google Scholar
• Jeong H , KimKP, JeongJHet al. Adjuvant gemcitabine plus cisplatin versus capecitabine in node-positive extrahepatic cholangiocarcinoma: the STAMP randomized trial. Hepatology77(5), 1540–1549 (2023).
   PubMed Web of Science ®Google Scholar
• Horgan AM , AmirE, WalterT, KnoxJJ. Adjuvant therapy in the treatment of biliary tract cancer: a systematic review and meta-analysis. J. Clin. Oncol.30(16), 1934–1940 (2012).
   PubMed Web of Science ®Google Scholar
• Tran Cao HS , ZhangQ, SadaYH, ChaiC, CurleySA, MassarwehNN. The role of surgery and adjuvant therapy in lymph node-positive cancers of the gallbladder and intrahepatic bile ducts. Cancer124(1), 74–83 (2018).
   PubMed Web of Science ®Google Scholar
• Primrose JN , FoxRP, PalmerDHet al. Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study. Lancet Oncol.20(5), 663–673 (2019).
   PubMed Web of Science ®Google Scholar
• Nakachi K , IkedaM, KonishiMet al. Adjuvant S-1 compared with observation in resected biliary tract cancer (JCOG1202, ASCOT): a multicentre, open-label, randomised, controlled, phase 3 trial. Lancet401(10372), 195–203 (2023).
   PubMed Web of Science ®Google Scholar
• Vogel A , BridgewaterJ, EdelineJet al. Biliary tract cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann. Oncol.34(2), 127–140 (2023).
   PubMed Web of Science ®Google Scholar
• Nakamura H , AraiY, TotokiYet al. Genomic spectra of biliary tract cancer. Nat. Genet.47(9), 1003–1010 (2015).
   PubMed Web of Science ®Google Scholar
• Simona T , GiovanniB. Mutational Landscape of Cholangiocarcinoma According to Different Etiologies: A Review. Cells12(9), 1216 (2023).
   PubMed Web of Science ®Google Scholar
• Weinberg BA , XiuJ, LindbergMRet al. Molecular profiling of biliary cancers reveals distinct molecular alterations and potential therapeutic targets. J. Gastrointest. Oncol.10(4), 652–662 (2019).
   PubMed Web of Science ®Google Scholar
• Sabbatino F , VillaniV, YearleyJHet al. PD-L1 and HLA class I antigen expression and clinical course of the disease in intrahepatic cholangiocarcinoma. Clin. Cancer Res.22(2), 470–478 (2016).
   PubMed Web of Science ®Google Scholar
• Piha-Paul SA , OhDY, UenoMet al. Efficacy and safety of pembrolizumab for the treatment of advanced biliary cancer: results from the KEYNOTE-158 and KEYNOTE-028 studies. Int. J. Cancer147(8), 2190–2198 (2020).
   PubMed Web of Science ®Google Scholar
• Doki Y , UenoM, HsuCHet al. Tolerability and efficacy of durvalumab, either as monotherapy or in combination with tremelimumab, in patients from Asia with advanced biliary tract, esophageal, or head-and-neck cancer. Cancer Med.11(13), 2550–2560 (2022).
   PubMed Web of Science ®Google Scholar
• Oh DY , LeeKH, LeeDWet al. Gemcitabine and cisplatin plus durvalumab with or without tremelimumab in chemotherapy-naive patients with advanced biliary tract cancer: an open-label, single-centre, phase 2 study. Lancet Gastroenterol. Hepatol.7(6), 522–532 (2022).
   PubMed Web of Science ®Google Scholar
• Oh D-Y , HeAR, QinSet al. Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer. NEJM Evid.1(8), EVIDoa2200015 (2022).
   PubMedGoogle Scholar
• Kelley RK , UenoM, YooCet al. Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet401(10391), 1853–1865 (2023).
   PubMed Web of Science ®Google Scholar
• Kudo M . Durvalumab plus tremelimumab in unresectable hepatocellular carcinoma. Hepatobiliary Surg. Nutr.11(4), 592–596 (2022).
   PubMed Web of Science ®Google Scholar
• Abou-Alfa GK , LauG, KudoMet al. Tremelimumab plus durvalumab in unresectable hepatocellular carcinoma. NEJM Evid.1(8), EVIDoa2100070 (2022).
   PubMedGoogle Scholar
• Oh D-Y , LeeK-H, LeeD-Wet al. Phase II study assessing tolerability, efficacy, and biomarkers for durvalumab (D)±tremelimumab (T) and gemcitabine/cisplatin (GemCis) in chemo-naive advanced biliary tract cancer (aBTC). J. Clin. Oncol.38(Suppl. 15), (2020).
   Web of Science ®Google Scholar
• Sahai V , GriffithKA, BegMSet al. A randomized phase 2 trial of nivolumab, gemcitabine, and cisplatin or nivolumab and ipilimumab in previously untreated advanced biliary cancer: bilT-01. Cancer128(19), 3523–3530 (2022).
   PubMed Web of Science ®Google Scholar
• Common Terminology Criteria for Adverse Events (CTCAE) Version 5. Published: November 27. US Department of Health and Human Services, National Institutes of Health, National Cancer Institute.
   Google Scholar
• Herdman M. , GudexC., LloydA.et al. Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L). Qual Life Res. 20(10), 1727–36 (2011).
   PubMed Web of Science ®Google Scholar
• Aaronson NK , AhmedzaiS, BergmanBet al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 85(5), 365–76 (1993).
   PubMed Web of Science ®Google Scholar
• Simon R , WittesRE, EllenbergSS. Randomized phase II clinical trials. Cancer Treat. Rep.69(12), 1375–1381 (1985).
   PubMedGoogle Scholar